Welcome to our dedicated page for Biocardia news (Ticker: BCDA), a resource for investors and traders seeking the latest updates and insights on Biocardia stock.
BioCardia, Inc. develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its recurring company updates center on the CardiAMP autologous cell therapy platform, CardiALLO allogeneic cell therapy programs, and device and software technologies used to deliver therapies to the heart, including the Helix transendocardial delivery catheter and Heart3D Fusion Imaging software.
News about BCDA commonly covers clinical results in ischemic heart failure with reduced ejection fraction, FDA and Japan PMDA regulatory interactions, patent protection for procedure-planning and navigation technology, and annual financial results. Company communications also address the role of Helix and related vascular navigation platforms in minimally invasive intramyocardial delivery of therapeutic and diagnostic agents.
BioCardia, Inc. (NASDAQ: BCDA) announced the activation of the pivotal CardiAMP Chronic Myocardial Ischemia Trial, studying the safety and efficacy of CardiAMP cell therapy for patients with refractory angina. The FDA has approved the trial, which will enroll up to 343 patients across 40 sites. The first site initiation occurred at the University of Florida, with patient recruitment expected soon. The CMS will reimburse investigational sites similar to the CardiAMP Heart Failure Trial. This trial aims to address a significant unmet clinical need affecting 600,000 to 1.8 million patients in the U.S.
Summary not available.